×

Please Remove Adblock
Adverts are the main source of Revenue for DoveMed. Please remove adblock to help us create the best medical content found on the Internet.

N-Telopeptide Cross-Links Urine Test

Last updated Aug. 21, 2016


What are other Names for this Test? (Equivalent Terms)

  • NTx Urine Test

What is N-Telopeptide Cross-Links Urine Test? (Background Information)

  • N-Telopeptide cross-links (NTx) are protein fragments created as a result of bone breakdown. NTx is used as a marker for bone degradation in disorders such as osteoporosis and osteopenia
  • Bone is made up of bone cells separated by bone matrix. About 90% of bone matrix is comprised of collagen, which has been cross-linked to make it stronger. The remaining components are inorganic salts such as bone mineral (hydroxyapatite)
  • Bone degradation causes the breakdown of these collagen fibers, which forms the telltale NTx fragments. The bone degradation is also carried out naturally by cells called osteoclasts. It occurs when calcium reserves are low, and as a normal part of bone maintenance and repair
  • Bone degradation is accelerated during conditions, such as osteoporosis and osteopenia, along with other bone disorders. NTx levels are significantly elevated in these cases
  • The N-Telopeptide Cross-Links Urine Test helps determine the levels of NTx in urine. It aids in the diagnosis of bone disorders such as osteoporosis

What are the Clinical Indications for performing the N-Telopeptide Cross-Links Urine Test?

Following are the clinical indications for performing the N-Telopeptide Cross-Links Urine Test: 

  • Monitoring the effects of antiresorptive therapy
  • Frequent and/or unusual bone fractures
  • Loss of height
  • Hair loss
  • Brittle nails
  • Fatigue 
  • Developmental issues, such as delayed onset of puberty

How is the Specimen Collected for N-Telopeptide Cross-Links Urine Test?

Following is the specimen collection process for N-Telopeptide Cross-Links Urine Test:

Sample required: Urine

Process of obtaining a sample in adults: Urination into a sterile container over a 24-hour period.

Preparation required: It is recommended to drink 6 to 8 glasses of water or other fluids prior to the test.

What is the Significance of the N-Telopeptide Cross-Links Urine Test Result?

The following is the significance of the N-Telopeptide Cross-Links Urine Test:

  • A high value, greater than 65 mM BCE/mmol creatinine in women and 51 mM BCE/mmol creatinine in men, for the test may point to a diagnosis of the following conditions:
    • Osteoporosis
    • Osteopenia
    • Paget’s disease
    • Advanced bone tumors
    • Acromegaly
    • Hypoparathyroidism
    • Hypothyroidism 
  • A low value, less than 5 mM BCE/mmol creatinine in women and 3 mM BCE/mmol creatinine in men, for the test may point to a diagnosis of the following conditions:
    • Hypoparathyroidism
    • Hypothyroidism 

The laboratory test results are NOT to be interpreted as results of a "stand-alone" test. The test results have to be interpreted after correlating with suitable clinical findings and additional supplemental tests/information. Your healthcare providers will explain the meaning of your tests results, based on the overall clinical scenario.

Additional and Relevant Useful Information:

Certain medications that you may be currently taking may influence the outcome of the test. Hence, it is important to inform your healthcare provider of the complete list of medications (including any herbal supplements) you are currently taking. This will help the healthcare provider interpret your test results more accurately and avoid unnecessary chances of a misdiagnosis.

What are some Useful Resources for Additional Information?

The following DoveMed website link is a useful resource for additional information: http://www.dovemed.com/bone-markers/

Please visit our Laboratory Procedures Center for more physician-approved health information:

http://www.dovemed.com/common-procedures/procedures-laboratory/

References and Information Sources used for the Article:

Kee, J. L. (2010). Laboratory and diagnostic tests with nursing implications (8th ed.). Upper Saddle River, NJ: Pearson.

Martini, F., Nath, J. L., & Bartholomew, E. F. (2012). Fundamentals of anatomy & physiology (9th ed.). San Francisco: Benjamin Cummings.

Williamson, M. A., Snyder, L. M., & Wallach, J. B. (2011). Wallach's interpretation of diagnostic tests (9th ed.). Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins.

Helpful Peer-Reviewed Medical Articles:

Tamiya, M., Tokunaga, S., Okada, H., Suzuki, H., Kobayashi, M., Sasada, S., ... & Hattori, M. (2013). Prospective study of urinary and serum cross-linked N-telopeptide of type I collagen (NTx) for diagnosis of bone metastasis in patients with lung cancer. Clinical lung cancer, 14(4), 364-369.

Aktas, B., Kasimir-Bauer, S., Lehmann, N., Kimmig, R., & Tewes, M. (2013). Validity of bone marker measurements for monitoring response to bisphosphonate therapy with zoledronic acid in metastatic breast cancer. Oncology reports, 30(1), 441-447.

Chow, E., DeAngelis, C., Chen, B. E., Azad, A., Meyer, R. M., Wilson, C., ... & Greenland, J. (2015). Effect of re-irradiation for painful bone metastases on urinary markers of osteoclast activity (NCIC CTG SC. 20U). Radiotherapy and Oncology, 115(1), 141-148.

Lara, P. N., Ely, B., Quinn, D. I., Mack, P. C., Tangen, C., Gertz, E., ... & Thompson, I. M. (2014). Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421. Journal of the National Cancer Institute, dju013.

Zhang, Y., Yi, M., Cao, J., Hou, C., Zhou, Y., & Zhong, Y. (2016). Serum cross-linked N-telopeptide of type I collagen for the diagnosis of bone metastases from solid tumours in the Chinese population: Meta-analysis. Journal of International Medical Research, 44(2), 192-200.

Amir, E., Freedman, O., Carlsson, L., Dranitsaris, G., Tomlinson, G., Laupacis, A., ... & Clemons, M. (2013). Randomized feasibility study of de-escalated (every 12 wk) versus standard (every 3 to 4 wk) intravenous pamidronate in women with low-risk bone metastases from breast cancer. American journal of clinical oncology, 36(5), 436-442.

Reviewed and Approved by a member of the DoveMed Editorial Board
First uploaded: Aug. 21, 2016
Last updated: Aug. 21, 2016